A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis

Kim, Su Jin; Chang, Suhwan; Lee, Yangsoon; Kim, Na Young; Hwang, Yeonsil; Min, Hye Jin; Yoo, Kyung-Sook; Park, Eun Hye; Kim, Seokho; Chung, Young-Hwa; Park, Young Woo

doi:10.1016/J.BBRC.2014.10.056

Title: A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis

Full Record
Other Related Research

Abstract

Highlights: • PMAb83, a human monoclonal antibody against PAUF, impaired tumor progression in vivo. • PMAb83 attenuated aggressiveness of tumor cells and suppressed angiogenesis. • PMAb83 in combination with gemcitabine conferred improved survival of mouse model. - Abstract: Pancreatic adenocarcinoma up-regulated factor (PAUF) is expressed in pancreatic ductal adenocarcinoma (PDAC) and plays an important role in tumor progression and metastasis. Here we evaluate the anti-tumor efficacy of a human monoclonal antibody against PAUF, PMAb83, to provide a therapeutic intervention to treat the disease. PMAb83 reduced tumor growth and distant metastasis in orthotopically xenografted mice of human PDAC cells. PMAb83 treatment retarded proliferation along with weakened aggressiveness traits of the carcinoma cells. AKT/β-catenin signaling played a role in the carcinoma cell proliferation and the treated xenograft tumors exhibited reduced levels of β-catenin and cyclin D1. Moreover PMAb83 abrogated the PAUF-induced angiogenic responses of endothelial cells, reducing the density of CD31{sup +} vessels in the treated tumors. In combination with gemcitabine, PMAb83 conferred enhanced survival of xenografted mice by about twofold compared to gemcitabine alone. Taken together, our findings show that PMAb83 treatment decreases the aggressiveness of carcinoma cells and suppresses tumor vascularization, which culminates in mitigated tumor growth and metastasis withmore »« less

Authors:

Kim, Su Jin ^[1]; Chang, Suhwan ^[2]; Lee, Yangsoon; Kim, Na Young; Hwang, Yeonsil; Min, Hye Jin; Yoo, Kyung-Sook; Park, Eun Hye; Kim, Seokho ^[1]; Chung, Young-Hwa ^[3]; Park, Young Woo ^[4]

Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon (Korea, Republic of)
Department of Biomedical Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul (Korea, Republic of)
BK21-plus, Department of Cogno-Mechatronics Engineering, Pusan National University, Busan (Korea, Republic of)
Aging Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon (Korea, Republic of)

Publication Date:: Fri Nov 07 00:00:00 EST 2014

OSTI Identifier:: 22416824

Resource Type:: Journal Article

Journal Name:: Biochemical and Biophysical Research Communications

Additional Journal Information:: Journal Volume: 454; Journal Issue: 1; Other Information: Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0006-291X

Country of Publication:: United States

Language:: English

Subject:: 60 APPLIED LIFE SCIENCES; ANGIOGENESIS; CARCINOMAS; CELL PROLIFERATION; COMPARATIVE EVALUATIONS; HUMAN POPULATIONS; IN VIVO; METASTASES; MICE; MONOCLONAL ANTIBODIES; PANCREAS; TUMOR CELLS; VEINS

Citation Formats


                    Kim, Su Jin, New Drug Development Center, Osong Medical Innovation Foundation, Cheongwon, Chungbuk, Chang, Suhwan, Lee, Yangsoon, Kim, Na Young, Hwang, Yeonsil, Min, Hye Jin, Yoo, Kyung-Sook, Park, Eun Hye, Kim, Seokho, Chung, Young-Hwa, Park, Young Woo, Koh, Sang Seok, E-mail: sskoh@dau.ac.kr, and Department of Biological Sciences, Dong-A University, Busan. A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis.  United States: N. p., 2014. 
        Web.  doi:10.1016/J.BBRC.2014.10.056.

Copy to clipboard


                    Kim, Su Jin, New Drug Development Center, Osong Medical Innovation Foundation, Cheongwon, Chungbuk, Chang, Suhwan, Lee, Yangsoon, Kim, Na Young, Hwang, Yeonsil, Min, Hye Jin, Yoo, Kyung-Sook, Park, Eun Hye, Kim, Seokho, Chung, Young-Hwa, Park, Young Woo, Koh, Sang Seok, E-mail: sskoh@dau.ac.kr, & Department of Biological Sciences, Dong-A University, Busan. A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis.  United States.  https://doi.org/10.1016/J.BBRC.2014.10.056

Copy to clipboard


                    Kim, Su Jin, New Drug Development Center, Osong Medical Innovation Foundation, Cheongwon, Chungbuk, Chang, Suhwan, Lee, Yangsoon, Kim, Na Young, Hwang, Yeonsil, Min, Hye Jin, Yoo, Kyung-Sook, Park, Eun Hye, Kim, Seokho, Chung, Young-Hwa, Park, Young Woo, Koh, Sang Seok, E-mail: sskoh@dau.ac.kr, and Department of Biological Sciences, Dong-A University, Busan. 2014.  
        "A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis".  United States.  https://doi.org/10.1016/J.BBRC.2014.10.056.

Copy to clipboard


                    
@article{osti_22416824,

  title        = {A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis},

  author       = {Kim, Su Jin and New Drug Development Center, Osong Medical Innovation Foundation, Cheongwon, Chungbuk and Chang, Suhwan and Lee, Yangsoon and Kim, Na Young and Hwang, Yeonsil and Min, Hye Jin and Yoo, Kyung-Sook and Park, Eun Hye and Kim, Seokho and Chung, Young-Hwa and Park, Young Woo and Koh, Sang Seok, E-mail: sskoh@dau.ac.kr and Department of Biological Sciences, Dong-A University, Busan},

  abstractNote = {Highlights: • PMAb83, a human monoclonal antibody against PAUF, impaired tumor progression in vivo. • PMAb83 attenuated aggressiveness of tumor cells and suppressed angiogenesis. • PMAb83 in combination with gemcitabine conferred improved survival of mouse model. - Abstract: Pancreatic adenocarcinoma up-regulated factor (PAUF) is expressed in pancreatic ductal adenocarcinoma (PDAC) and plays an important role in tumor progression and metastasis. Here we evaluate the anti-tumor efficacy of a human monoclonal antibody against PAUF, PMAb83, to provide a therapeutic intervention to treat the disease. PMAb83 reduced tumor growth and distant metastasis in orthotopically xenografted mice of human PDAC cells. PMAb83 treatment retarded proliferation along with weakened aggressiveness traits of the carcinoma cells. AKT/β-catenin signaling played a role in the carcinoma cell proliferation and the treated xenograft tumors exhibited reduced levels of β-catenin and cyclin D1. Moreover PMAb83 abrogated the PAUF-induced angiogenic responses of endothelial cells, reducing the density of CD31{sup +} vessels in the treated tumors. In combination with gemcitabine, PMAb83 conferred enhanced survival of xenografted mice by about twofold compared to gemcitabine alone. Taken together, our findings show that PMAb83 treatment decreases the aggressiveness of carcinoma cells and suppresses tumor vascularization, which culminates in mitigated tumor growth and metastasis with improved survival in PDAC mouse models.},

  doi          = {10.1016/J.BBRC.2014.10.056},

  url          = {https://www.osti.gov/biblio/22416824},
  journal      = {Biochemical and Biophysical Research Communications},

  issn         = {0006-291X},

  number       = 1,

  volume       = 454,

  place        = {United States},

  year         = {Fri Nov 07 00:00:00 EST 2014},

  month        = {Fri Nov 07 00:00:00 EST 2014}

}

Copy to clipboard

Journal Article:

https://doi.org/10.1016/J.BBRC.2014.10.056

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Gemcitabine-induced CXCL8 expression counteracts its actions by inducing tumor neovascularization

Journal Article Song, Yao; Baba, Tomohisa; Li, Ying-Yi; ... - Biochemical and Biophysical Research Communications

Patients with pancreatic ductal adenocarcinoma (PDAC) are frequently complicated with metastatic disease or locally advanced tumors, and consequently need chemotherapy. Gemcitabine is commonly used for PDAC treatment, but with limited efficacy. The capacity of gemcitabine to generate reactive oxygen species (ROS) in human pancreatic cancer cells, prompted us to examine its effects on the expression of pro-inflammatory cytokines and chemokines. We observed that gemcitabine enhanced selectively the expression of CXCL8 in human pancreatic cancer cells through ROS generation and NF-κB activation. In vitro blocking of CXCL8 failed to modulate gemcitabine-mediated inhibition of cell proliferation in human pancreatic cancer cells. Gemcitabine alsomore »« less
https://doi.org/10.1016/J.BBRC.2015.01.112
Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice

Journal Article Peran, Ivana; Dakshanamurthy, Sivanesan; McCoy, Matthew; ... - Gastroenterology

Pancreatic ductal adenocarcinomas (PDACs) are characterized by fibrosis and an abundance of cancer-associated fibroblasts (CAFs). Here, we investigated strategies to disrupt interactions among CAFs, the immune system, and cancer cells, focusing on adhesion molecule CDH11, which has been associated with other fibrotic disorders and is expressed by activated fibroblasts. We compared levels of CDH11 messenger RNA in human pancreatitis and pancreatic cancer tissues and cells with normal pancreas, and measured levels of CDH11 protein in human and mouse pancreatic lesions and normal tissues. We crossed p48-Cre;LSL-Kras^G12D/+;LSL-Trp53^R172H/+ (KPC) mice with CDH11-knockout mice and measured survival times of offspring. Pancreata were collectedmore »« less
https://doi.org/10.1053/j.gastro.2020.11.044

Full Text Available
The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42–44 MAPK, Akt, Bcl-2 and MMP13 pathways

Journal Article Tréhoux, Solange; Duchêne, Bélinda; Jonckheere, Nicolas - Biochemical and Biophysical Research Communications

Highlights: • Loss of MUC1 decreases proliferation and tumor growth via β-catenin and p42–44 MAPK. • Inhibition of MUC1 decreases cell migration and invasion through MMP13. • Loss of MUC1 decreases survival and increases apoptosis via Akt and Bcl-2 pathways. • Loss of MUC1 sensitizes cells to gemcitabine and 5-Fluorouracil chemotherapeutic drugs. - Abstract: MUC1 is an oncogenic mucin overexpressed in several epithelial cancers, including pancreatic ductal adenocarcinoma, and is considered as a potent target for cancer therapy. To this aim, we undertook to study MUC1 biological effects on pancreatic cancer cells and identify pathways mediating these effects. Our inmore »« less
https://doi.org/10.1016/J.BBRC.2014.12.025
Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging

Journal Article Yeh, Chi-Tai; Rao, Yerra; Ye, Min; ... - Toxicology and Applied Pharmacology

In continuation to our studies toward the identification of direct anti-cancer targets, here we showed that destruxin B (DB) from Metarhizium anisopliae suppressed the proliferation and induced cell cycle arrest in human colorectal cancer (CRC) HT29, SW480 and HCT116 cells. Additionally, DB induced apoptosis in HT29 cells by decreased expression level of anti-apoptotic proteins Bcl-2 and Bcl-xL while increased pro-apoptotic Bax. On the other hand, DB attenuated Wnt-signaling by downregulation of β-catenin, Tcf4 and β-catenin/Tcf4 transcriptional activity, concomitantly with decreased expression of β-catenin target genes cyclin D1, c-myc and survivin. Furthermore, DB affected the migratory and invasive ability of HT29more »« less
https://doi.org/10.1016/J.TAAP.2012.03.007
USP5 promotes tumorigenesis and progression of pancreatic cancer by stabilizing FoxM1 protein

Journal Article Li, Xin-Yan; Wu, Hai-Yun; Mao, Xiao-Fang; ... - Biochemical and Biophysical Research Communications

Increased ubiquitin-specific protease 5 (USP5) has been associated with tumorigenesis of malignancy including glioblastoma, melanoma and hepatocellular carcinoma. However, the role of USP5 in tumorigenesis of pancreatic ductal adenocarcinoma (PDAC) has not been studied yet. In this study, we demonstrated that USP5 was significantly upregulated in a panel of PDAC cell lines and correlated with FoxM1 protein expression. USP5 knockdown inhibited proliferation of PANC-1 and SW1990, two PDAC cell lines. In the mouse xenografted pancreatic tumor model, suppression of USP5 significantly decreased tumor growth, correlated with down regulation of FoxM1. Additionally, we found that overexpression of USP5 stabilized the FoxM1more »« less
https://doi.org/10.1016/J.BBRC.2017.08.040

Similar Records